CEPI puts $25M in­to Rift Val­ley fever vac­cine; Gates in­vests in AI for sci­en­tists in Africa in eq­ui­ty bid

Plus, Ole­ma and No­var­tis up­date an agree­ment for a breast can­cer tri­al, and Roche shares long-term da­ta for Vabysmo in mac­u­lar ede­ma.

CEPI puts $25M in­to vac­cine for Rift Val­ley fever: The Coali­tion for Epi­dem­ic Pre­pared­ness In­no­va­tion is giv­ing $25.9 mil­lion to Wa­genin­gen Biovet­eri­nary Re­search to ad­vance a live-at­ten­u­at­ed vac­cine for Rift Val­ley fever in­to a Phase I/IIa tri­al. CEPI said Tues­day that heavy rain and flood­ing are linked to out­breaks of the virus, which is pri­mar­i­ly spread by mos­qui­toes in sub-Sa­ha­ran Africa. “A RVF vac­cine will con­tribute to pre­pared­ness for po­ten­tial virus emer­gence in yet un­af­fect­ed re­gions like Eu­rope,” WB­VR’s Paul Wichgers Schreur said in a state­ment.  — Jaimy Lee

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER